Cbd oil for treating vulvodynia

Tetrahydrocannabinol Reduces Hapten-Driven Mast Cell Accumulation and Persistent Tactile Sensitivity in Mouse Model of Allergen-Provoked Localized Vulvodynia

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Associated Data

Abstract

Vulvodynia is a remarkably prevalent chronic pain condition of unknown etiology. An increase in numbers of vulvar mast cells often accompanies a clinical diagnosis of vulvodynia and a history of allergies amplifies the risk of developing this condition. We previously showed that repeated exposures to oxazolone dissolved in ethanol on the labiar skin of mice led to persistent genital sensitivity to pressure and a sustained increase in labiar mast cells. Here we sensitized female mice to the hapten dinitrofluorobenzene (DNFB) dissolved in saline on their flanks, and subsequently challenged them with the same hapten or saline vehicle alone for ten consecutive days either on labiar skin or in the vaginal canal. We evaluated tactile ano-genital sensitivity, and tissue inflammation at serial timepoints. DNFB-challenged mice developed significant, persistent tactile sensitivity. Allergic sites showed mast cell accumulation, infiltration of resident memory CD8 + CD103 + T cells, early, localized increases in eosinophils and neutrophils, and sustained elevation of serum Immunoglobulin E (IgE). Therapeutic intra-vaginal administration of Δ 9 -tetrahydrocannabinol (THC) reduced mast cell accumulation and tactile sensitivity. Mast cell-targeted therapeutic strategies may therefore provide new ways to manage and treat vulvar pain potentially instigated by repeated allergenic exposures.

Keywords: mast cells, dinitrofluorobenzene, hypersensitivity, chronic pain, vulvodynia, Δ 9 -tetrahydrocannabinol

1. Introduction

Vulvodynia is a complex, chronic vulvar pain condition without a clear underlying etiology that affects between 10 to 28% of women of reproductive age as assessed primarily in US urban populations [1,2]. Women who experience this particular form of genital pain often struggle to receive a diagnosis and are frequently unable to find an effective treatment. Along with painful sensitivity to touch, a clinical diagnosis of vulvodynia often includes an increase in mast cells, local overgrowth of nerves [3], and altered inflammatory responses of vulvar tissue-derived fibroblasts to in vitro yeast antigen stimulation [4,5]. A history of seasonal and cutaneous allergies doubles the risk for vulvodynia [6], and its incidence is linked with exposure to household and workplace cleaning chemicals [7]. We have previously reported that repeated exposures to the hapten oxazolone on the labiar skin of ND4 (Notre Dame re-derived) Swiss Webster female mice recapitulate key clinical symptoms, i.e., painful ano-genital sensitivity to touch, increased nerve growth and an accumulation of mast cells [8,9]. We also found that local mast cell depletion by intra-labiar injections of basic secretagogue compound 48/80 (c48/80) decreased pain sensitivity [8]. Here, we investigated whether this effect was hapten-specific by exposing ND4 Swiss female mice to dinitrofluorobenzene (DNFB) instead of oxazolone. Allergic exposure to DNFB in mice induces contact hypersensitivity [10] and airway hyperresponsiveness [11], both of which are mast cell driven. Dermal mast cells and dendritic cells are the first responders to DNFB in the skin and orchestrate the subsequent T cell driven inflammation [12]. Given the importance of mast cells in allergen-driven vulvar pain, the capacity for specific induction of mast cell driven responses was critical to our choice of DNFB as the hapten allergen for these experiments. Furthermore, we used a non-traditional saline vehicle so that we could apply DNFB challenges inside the vaginal canal of ND4 mice. Mouse models of contact hypersensitivity typically use harsher, drying organic solvents such as ethanol or acetone to deliver hapten allergens onto the skin [13,14]. Given that clinical tests for vulvodynia [1] and associated inflammation [4,5] are conducted on the mucosal-like vulvar tissue, we adapted our protocol to apply DNFB dissolved in normal saline within the vaginal canal of mice that had been previously sensitized to DNFB on the shaved flank and measured changes in ano-genital sensitivity to touch and pressure, as well as inflammatory responses in the affected tissue. Finally, we assessed the effect of therapeutic intra-vaginal applications of Δ 9 -tetrahydrocannabinol (THC) on the abundance of mast cells and painful sensitivity.

2. Results

2.1. Ten Exposures to Dinitrofluorobenzene (DNFB) Dissolved in Saline on the Labiar Skin of Previously Sensitized ND4 Swiss Mice Induce Local and Systemic Inflammatory Responses

To demonstrate that allergic tissue changes occur in response to DNFB dissolved in saline instead of a more typical, harsher vehicle such as acetone, we measured mast cell and T cell infiltration as well as changes in inflammatory cytokines in the allergic skin of previously sensitized ND4 female mice after 10 DNFB challenges. Labiar mast cell density increased in flank-sensitized mice challenged with 10 daily topical DNFB administrations to the labiar skin compared to mice challenged with saline; there was a four-fold increase one day after the completion of challenges, and a seven-fold increase at 21 days ( Figure 1 A,B). Interestingly, serum IgE levels were significantly elevated compared to controls challenged only with saline 1 day after 10 DNFB challenges and remained so 42 days after challenges were completed ( Figure 1 C). Tissue eosinophil peroxidase and tissue myeloperoxidase levels increased sharply in DNFB-challenged mice vs. saline-treated controls one day after 10 challenges and resolved to levels indistinguishable from controls by 21 days after challenge cessation ( Figure 1 D,E). One day after the 10th DNFB administration, flow cytometric analysis of dissociated flank skin revealed a significant accumulation of CD3 + , CD4 + , activated CD4 + CD44 + , CD8 + , and resident memory CD8 + CD103 + in hapten-challenged but not in control mice ( Figure 1 F). mRNA transcripts encoding IL-6 and IFN-γ were upregulated 8 and 3-fold respectively in DNFB- vs. saline-challenged mice 1 day post challenge cessation. IL-6 mRNAs remained slightly upregulated over controls at 21 days after 10 DNFB challenges ( Figure 1 G). IFN-γ, which has been shown to drive mast cell-mediated immune responses [15], was increased to 15-fold in DNFB- vs. saline-treated mice 21 days after 10 labiar challenges. All visually detectable signs of irritation (slight redness) resolved within 2 days of cessation of DNFB challenges. Since the inflammatory effects of DNFB in more typical organic solvent vehicles have, historically, been characterized mostly in inbred mouse strains, we verified that outbred ND4 female mice sensitized on the flank and subsequently challenged on the labiar skin with DNFB dissolved in acetone showed increases in local mast cell abundance and abundances of transcripts encoding IL-6 and IFN-γ (Figure S1A–C). However, we noticed that the harsher acetone solvent caused more dryness of the labiar skin compared to the saline vehicle we used for these studies.

Repeated topical dinitrofluorobenzene (DNFB) exposure on the labiar skin in previously sensitized ND4 mice results in increased abundance of local mast cells, higher levels of IL-6 and IFN-γ transcripts, elevated serum IgE, greater myeloperoxidase and eosinophil peroxidase activity, and increased numbers of infiltrating T cells. (A) Representative sections at 200x magnification showing FITC (fluorescein-isothiocyanate)-Avidin-stained mast cell granules in labiar tissues of DNFB vs. saline-challenged mice 1 day and 21 days after 10 challenges; (B) Relative intensity of Avidin-stained mast cell granules in the labiar skin of DNFB vs. saline-challenged mice 1 day and 21 days after 10 labiar DNFB challenges. n= 3; (C) Total IgE levels in serum measured 1 day, 21 days, and 42 days after 10 challenges with DNFB or saline in previously sensitized mice and in age-matched untreated mice (NT). ** and * represent p-values of p < 0.01 and p < 0.05 respectively. n = 3–6; (D) Eosinophil peroxidase and (E) myeloperoxidase levels in the labiar tissue, normalized to tissue weight, 1 and 21 days after 10 DNFB or saline challenges. *** represents p-values of p < 0.001. n = 3–6; (F) CsD3 + , CD4 + , CD4 + CD25 + , CD4 + CD44 + , CD4 + CD25 + CD44 + , CD8 + , and CD8 + CD103 + cell numbers in flank tissues derived from previously sensitized mice challenged with either DNFB or saline vehicle on the flank. ** and * represent p-values of p < 0.01 and p < 0.05 respectively. n = 6; nd = not detected; (G) Relative abundances of IL-6 and IFN-γ mRNAs in the labiar tissue of DNFB- vs. saline-challenged, previously sensitized mice 1 day and 21 days after 10 DNFB challenges, each normalized to β2-microglobulin (housekeeping) mRNA levels. n = 3.

2.2. Ten DNFB Administrations on the Labiar Skin, or in the Vaginal Canal, of Previously Sensitized ND4 Swiss Mice Provoke Persistent Vulvar Mechanical Tactile Sensitivity

Since repeated exposures to DNFB dissolved in saline provoked inflammatory responses in keratinized labiar skin, we next assessed the potential for DNFB/saline to provoke tactile ano-genital sensitivity when administered on the labiar skin or, separately, into the vaginal canal of ND4 mice. We measured tactile sensitivity using an electronic von Frey meter at serial timepoints after 10 DNFB challenges applied on the labiar skin or pipetted into the vaginal canal in previously sensitized ND4 Swiss mice. One day after cessation of challenges, mice repeatedly exposed to DNFB topically on the labiar tissue ( Figure 2 A) or directly into the vaginal canal ( Figure 2 B) showed significantly increased tactile sensitivity compared to mice similarly exposed to 0.9% saline. DNFB treated mice had a ~60% decrease from baseline withdrawal measurements after DNFB exposure in both tissues one day after the 10th challenge. Mice treated with saline had a ~30% decrease in withdrawal threshold to touch. This localized hapten-dependent increase in tactile sensitivity persisted past 21 days post 10th DNFB exposure on the labiar tissue and in the vaginal canal long after resolution of overt inflammation in the tissues. Both DNFB and saline challenged mice returned to baseline withdrawal values by 42 days after the last DNFB exposure. At all timepoints after the 10th challenge, mice treated with saline did not show painful responses; they had a percent decrease from baseline value lower than the hyperalgesia cutoff of a 33% difference between average baseline and post-treatment values described by us and others [8,9,16]. ND4 female mice sensitized on the flank and subsequently challenged on the labiar skin with DNFB dissolved in acetone also displayed heightened genital sensitivity to pressure one day after the cessation of challenges (Figure S1D).

Ten daily DNFB challenges on the labiar skin and in the vaginal canal results in increased sensitivity that persists 21 days post tenth challenge. (A) Percent decrease from baseline measurements 1, 21, and 42 days after 10 labiar challenges, n = 18–27 and (B) 1, 14, 21, and 28 days post vaginal canal challenge. Only post-treatment withdrawal responses that show a 33%, represented by blue dotted line, or greater decrease from baseline withdrawal thresholds are considered hyperalgesic. *** and * represent a p-value of p < 0.001 and p < 0.05 respectively n = 9–18.

2.3. Ten DNFB Exposures into the Vaginal Canals of Previously Sensitized ND4 Swiss Mice Induce Local and Systemic Inflammatory Responses

In addition to provoking tactile ano-genital sensitivity when applied inside the vaginal canal, repeated administration of DNFB into the vaginal canal of ND4 mice produced inflammatory changes in abundances of cells and molecules similar to those we described above in labiar skin. Mast cells accumulated at ~3-fold higher levels in the vaginal canal tissues of DNFB-challenged vs. saline-challenged mice and persisted through 21 days after 10 hapten administrations ( Figure 3 A,B). mRNA transcripts encoding IL-6 were slightly upregulated at 21 days after 10 DNFB challenges while IFN-γ transcripts were upregulated ~4-fold one day after the 10th challenge and ~2-fold at 21 days ( Figure 3 C). Serum IgE, tissue eosinophil peroxidase and tissue myeloperoxidase levels were all significantly elevated in DNFB- vs. saline-challenged mice a day after 10 challenges to the vaginal canal ( Figure 3 D–F). Mast cells ( Figure 3 G), B cells, CD4 + T cells, and CD8 + T cells ( Figure 3 H) were elevated in the draining iliac lymph nodes at 1 day, 3 days, and 7 days in mice challenged 10 times daily with DNFB in the vaginal canal as compared to saline-challenged controls.

Repeated DNFB exposure in the vaginal canal provokes increased local mast cell density, upregulation of IL-6 and IFN-γ expression, increased IgE concentration in the serum, and increased numbers of B cells, T cells, and mast cells in the iliac lymph nodes. (A) Representative immunofluorescent images at 200X magnification of FITC-Avidin stained mast cells in vaginal canal tissue of DNFB and saline challenged mice 1 day and 21 days post 10th challenge; (B) Relative fluorescent intensity of DNFB challenged mice 1 day and 21 days post 10 challenges compared to saline challenged mice. n = 3; (C) Relative transcript abundance of IL-6 and IFN-γ mRNAs in the vaginal canal tissue normalized to β2-microglobulin (housekeeping) mRNA levels. n = 5–9; Local (D) eosinophil peroxidase and (E) myeloperoxidase levels in the vaginal canal, normalized to tissue weight, 1 day after 10 DNFB or saline challenges. * represents a p-value of p < 0.05. n = 3; (F) Total IgE levels in the serum measured 1 day after 10 challenges with DNFB or saline in previously sensitized mice and in age-matched untreated mice (NT). ** represents a p-value of p < 0.01. n = 4–6; Cell counts of (G) mast cells, and (H) B cells, CD4 + T cells, and CD8 + T cells in the iliac lymph nodes 1 day, 3 days, and 7 days post 10th challenge. ** and * represent a p-value of p < 0.01 and p < 0.05 respectively. n = 6.

2.4. Repeated Δ 9 -Tetrahydrocannabinol (THC) Application Reduces Tactile Sensitivity and Mast Cell Density after 10 Exposures to DNFB in the Vaginal Canals of Previously Sensitized ND4 Mice

Gaffal and colleagues have demonstrated the anti-inflammatory activity of THC, the main psychoactive phyto-cannabinoid of cannabis, in DNFB-driven dermatitis in mice [16]. Others have elucidated the effects of THC on mast cell function in oxazolone-driven dermatitis [17]. Here we tested the potential of THC, administered topically inside the vaginal canals of DNFB-challenged mice, to alleviate tactile sensitivity and reduce mast cell accumulation. We pipetted the cannabinoid THC (in saline) directly into the vaginal canal of sensitized ND4 Swiss mice for six consecutive days starting one day after 10 DNFB administrations within the vaginal canal. One day after six THC applications i.e., on day 7 after 10 DNFB challenges, mice showed decreased sensitivity compared to mice that were challenged with DNFB but not treated with vaginal THC. ( Figure 4 A). THC treated mice had a ~30% decrease from baseline withdrawal values while the mice with no THC treatment showed a 60% decrease from baseline withdrawal thresholds. The decrease in sensitivity in the THC treated mice was accompanied by a decrease in local mast cell density ( Figure 4 B,C).

See also  Cbd oil for dogs eugene

Repeated local Δ 9 -tetrahydrocannabinol (THC) application after ten DNFB challenges in the vaginal canal results in decreased sensitivity and local mast cell densities compared to controls. (A) Sensitivity measured 1 day after 10 DNFB challenges and either 6 THC treatments or no treatment (NT). Only post-treatment withdrawal responses that show a 33%, represented by the dotted line, or greater decrease from baseline withdrawal thresholds are considered hyperalgesic. ** represents a p-value of p < 0.01. n = 17–18; (B) Representative immunofluorescence images at 200x magnification showing fluorescent FITC-Avidin-stained mast cell granules in vaginal canals of THC treated and not treated mice; (C) Relative intensity of Avidin-stained mast cell granules in vaginal canals of THC treated mice calculated as fold change over non-THC treated mice. n = 3.

3. Discussion

The contributions of mast cells to pain pathologies have been well studied in recent years [18]. These “tunable” effectors of tissue pathology [19] are now known to contribute to protective painful responses to noxious stimuli [20,21] as well as to acute and chronic pain conditions such as migraines [22], sickle cell pain [23], irritable bowel disorders [24] and pain associated with neuropathic and neurological diseases [25,26]. Mast cell increases in vulvar biopsy samples from vulvodynia patients were first reported over a decade ago [3,27] but are not ubiquitous in all patients [28]. Despite its surprisingly high prevalence vulvodynia remains a diagnosis of exclusion [29] and its pathophysiology is poorly understood. Medical histories of yeast infections [30], other urinogenital infections [31], depression and anxiety [32], and allergies [6] have all been associated with elevated vulvodynia risk. However, these possibly overlapping but likely importantly distinct etiologies and relevant underlying mechanisms have not been differentiated and there are no known biomarkers to appropriately diagnose sub-types of vulvar pain. As a result, efficacious, targeted therapies are yet to be developed for the management of this condition.

There are very few established pre-clinical models of persistent genital pain that can be used to investigate disease process, biomarkers, and therapies. We have, both previously [8,9] and here, adapted laboratory hapten-based mouse contact hypersensitivity protocols to show that mast cell accumulation following repeated allergen exposures lasts weeks beyond the resolution of overt inflammation. It has been previously shown that mast cell accumulation in the airways following exposure to the allergen ovalbumin is dependent on the presence of regulatory T cells [33] and mast cell-mediated tissue remodeling in chronic asthma-like disease in mice is dependent on IFN-γ [34]. Here we’ve reported the early accumulation of regulatory CD4 + CD25 + T cells in DNFB/saline-challenged skin that may potentially serve to recruit mast cells to the site of the reaction, and also infiltration of resident memory CD8 + CD103 + cells that can potentially serve as a key source of IFN-γ [35]. Importantly, IFN-γ and IL-6 are elevated both in the local tissue of challenged mice in our experiments, and in biopsies of vulvodynia patients versus controls [5]. The systemic increase in IgE we measured following DNFB challenges is also notable since IgE can serve as a survival factor for mast cells [36] along with IL-6 [37]. Interestingly while acute inflammatory markers such as neutrophil and eosinophil infiltration resolved rather rapidly after the cessation of DNFB challenges, mast cell accumulation, increase in IFN-γ mRNAs and heightened serum IgE levels persisted three weeks or longer along with detectable painful responses showing strong association between mast cell accumulation and genital pain ( Figure 5 ).

Repeated DNFB exposures on the skin lead to accumulation of regulatory T cells, resident memory T cells and mast cells. Mast cell increases are correlated with increased tactile sensitivity; therapeutic intra-vaginal THC application reduces mast cell density and tactile pain. Solid arrows indicate the hypothesized mechanisms proposed in this model. Dotted lines indicate previously published experimental observations of the contributions of regulatory T cells, IFN-γ and circulating IgE to mast cell recruitment, survival and activity in the tissue. T-bars indicate suppression of mast cell accumulation and tactile sensitivity following THC application. Artwork by Amy Pelz.

Administration of DNFB using a saline vehicle also allowed us to apply allergen directly into the vaginal canal of ND4 mice to simulate contact dermatitis-driven exposures and inflammation in mucosal tissues that are more similar to the vestibular tissues associated with a diagnosis of vulvodynia [1]. We saw similar persistent tactile pain responses and mast cell accumulation, as well as increases in IFN-γ mRNAs following intra-vaginal applications of DNFB/saline in ND4 mice. Wang et al. observed increases in mast cells in the draining lymph node after dermal DNFB/acetone exposure [38]; these mast cells were critical to subsequent T cell recruitment and activity. After intra-vaginal DNFB/saline administration, mast cells expanded in the iliac lymph nodes of ND4 mice between 1 and 7 days. This, along with increases in serum IgE and early spikes in eosinophil and neutrophil activity in the mucosal tissue of the vaginal canal confirms that intra-vaginal administration of DNFB in a novel saline vehicle induced allergic inflammation that was accompanied by persistent painful sensitivity to touch.

We also saw a modest increase in the density of cutaneous sensory nerves in the vaginal canal and labiar skin tissues of sensitized mice challenged with DNFB vs. control mice challenged with saline (Figure S2). Nerve Growth Factor (NGF) and Cell Adhesion Molecule -1 (CADM1) mRNAs are slightly upregulated in labiar skin of sensitized mice after three challenges with DNFB dissolved in acetone (Figure S1E). Mast cells and nerves often jointly regulate tissue inflammation and pathology [18,39]; mast cells can secrete NGF [40] and CADM1 is an important component of mast cell-nerve synapses that regulate the pathophysiology of atopic dermatitis lesions [41]. Therefore, it is possible that the accumulation of mast cells in DNFB/saline-treated tissues of the vaginal canal modulates increased density and activation of local nerves contributing to the painful response to touch and pressure.

While we see tissue mast cell numbers increase following repeated applications of both oxazolone [8,9] and DNFB (using either acetone or saline as vehicles), Farmer and colleagues [16] report that in their model of genital pain provoked by repeated vulvovaginal candidiasis, no mast cell increases were detected in the vaginal canal tissues. Therefore, non-normative accumulation of mast cells in vulvodynia patients may be a biomarker for an allergy-driven etiology of vulvar pain but not vulvar pain that stems from other root causes such as repeated yeast infections. Administration of mast cell granule stabilizer cromolyn sodium has been shown to have no significant therapeutic benefit for patients with vulvar vestibulitis who show increased mast cell numbers by biopsy [42]. This is concordant with our observation that while mast cells increase in numbers at the painful site, their contribution to the pain pathology appears to be driven by their presence rather than degranulation. We have, in fact, previously shown that local, transient removal of accumulated mast cells via secretagogue c48/80-mediated degranulation is associated with a transient relief from painful responses to pressure [8]. Here, we show that daily therapeutic topical administration of THC in the vaginal canal for six days resulted in a decrease in painful sensitivity to pressure in the ano-genital region as well as reduced local mast cell density in the vaginal canal tissue of previously sensitized mice challenged with 10 doses of DNFB in the vaginal canal. While the actions of endocannabinoids and cannabis-based medicines on neurological pain pathways are well established [43], here we observed changes in mast cell numbers following THC administration. Cannabinoid receptor-1 (CB1R) agonists have been shown to directly downregulate activity of cultured RBL-2H3 mast cells and mast cell activity in oxazolone-dermatitis [18] and topical THC has been shown to reduce symptoms of DNFB-dermatitis independent of CB1 and CB2 receptors [16]. Cannabinoid receptor-specific mechanisms have also been shown to mitigate mast cell activation, neurogenic inflammation and pain associated with sickle cell disease [44]. Singh and colleagues showed that a CB2 receptor agonist ameliorated dextran sodium sulfate-driven colitis in IL10−/− mice along with a reduction of mast cell numbers in the lamina propria and mesenteric lymph nodes although the specific mechanisms of cannabinoid-driven mast cell reduction have yet to be elucidated [45]. With recent changes in regulatory practices around therapeutic and recreational marijuana use, the use of cannabis products for medical purposes including pain relief is rapidly expanding [46]. A recent meta-analysis of randomized clinical trial reports [47] concluded that cannabis-based medicines might be effective for chronic pain but are more efficacious for neuropathic pain and that adverse effects are more likely with oral and mucosal administration rather than inhalation. Given these and other caveats, more thorough risk-benefit analyses must be conducted before cannabis-based therapies can be recommended more broadly. Our results here suggest, however, that local, topical cannabinoid administration could potentially reduce pathological mast cell accumulation that drives chronic vulvar pain, and therefore deserves more thorough examination in pre-clinical and clinical settings.

Vulvodynia is a complex, multi-factorial pain condition that likely stems from a wide variety of underlying causes and unfolds in the diverse inflammatory contexts of individual experiences and medical histories. With the caveat that the complexity of this syndrome cannot be captured in a single pre-clinical model, our findings support the biological plausibility of the epidemiological connections between vulvar pain and allergies and suggest that otherwise unexplained vulvar pain accompanied by tissue mast cell abnormalities may potentially be alleviated by local depletion of mast cells.

4. Materials and Methods

4.1. Animal Usage

Eight to twelve-week-old female ND4 Swiss mice (Harlan Laboratories, Indianapolis, IN, USA) were housed in Macalester College’s animal facility, which maintains 12-h light/dark cycle room conditions. Mice are able to access food and water at all times. Macalester College’s animal ethics committee, the Institutional Animal Care and Use Committee, approved all experimental protocols (B16Su1 approved 1 July 2016).

4.2. DNFB Administration: Sensitization and Challenge

4.2.1. Labiar and Vaginal Canal Challenges

ND4 female Swiss mice were shaved on the right flank (15 mm × 15 mm) 1 or 4 days prior to sensitization depending on whether or not sensitivity measurements were taken during that experiment. A 5 mm × 5 mm area of labiar skin was shaved for labiar allergen application. All mice were sensitized with a topical application of 25 µL of 0.5% DNFB (Sigma-Aldrich St. Louis, MO, USA, #D1529-10ML) dissolved in 0.9% saline on the shaved flank. Four days after sensitization, mice were challenged for 10 consecutive days on the shaved labiar skin (10 µL per labium) or in the vaginal canal with a total of 20 µL of 0.3% DNFB dissolved in 0.9% saline. For vaginal canal challenges, mice were gently restrained in a belly-up position, while placing a P20 pipette with a 0.1–20 µL pipette tip by the vaginal opening and gently pipetting the solution into the vaginal canal. To minimize leakage and ensure that the full volume has been administered into the vaginal canal, mice were held in position for an additional 10 s.

4.2.2. THC Treatment

One day after the 10th DNFB vaginal canal challenge, previously sensitized mice were treated with 50 µg of THC (Sigma-Aldrich, St. Louis, MO, USA; methanol evaporated) dissolved in 20 µL of 0.9% saline in the vaginal canal using the same vaginal canal challenge procedure detailed above. Olive oil (Sigma-Aldrich, St. Louis, MO, USA) was added to the THC solution one drop at a time to help THC dissolve into 0.9% saline. THC was administered daily for 6 consecutive days.

4.2.3. Electronic Von Frey Measurements

Mechanical tactile sensitivity was measured in the labiar region, specifically the ano-genital ridge, using an Electronic von Frey Anesthesiometer (IITC Corporation, Woodland Hills, CA, USA) and techniques established and refined by our research group [48]. Two baseline withdrawal thresholds were taken 1 and 2 days before hapten exposure. Mice were assigned to treatment groups to ensure similar average baseline values between treatment groups (±0.01). Sensitivity was assessed at serial timepoints after the last DNFB challenge or last THC treatment by one investigator who remained blinded to treatment. To calculate percent decrease from baseline, average post-challenge withdrawal values were subtracted from average baseline values for each mouse. Percent decrease from baseline values were averaged across each treatment group. We defined the threshold for pain sensitivity as a 33% decrease in withdrawal force from baseline to treatment [8,9,49].

4.2.4. Tissue Collection

Serum, iliac lymph nodes, spleen, flank tissue, labiar tissue, and vaginal canal were collected from mice euthanized by 100% CO2 inhalation at various predetermined experimental timepoints. Fat was scraped off the flank and labiar tissue samples and half of the vaginal canal furthest from the introitus was discarded. Tissue samples were flash-frozen in liquid nitrogen and stored at −80 °C.

See also  Cbd oil for dogs and aggression
4.2.5. RNA Extraction and Quantitative Real-Time Reverse Transcriptase PCR (qRT-PCR)

Total RNA from vaginal canal tissue and labiar skin with fat removed (Total RNA Mini Kit, Midwest Scientific, St. Louis, MO, USA), was eluted with RT-PCR grade water, and quantified in ng/µL RNA with a Nanodrop ND-1000 Spectrophotometer (ThermoScientific, Wilmington, DE, USA). The RNA was then used in a semi-quantitative reverse-transcriptase polymerase chain reaction (sqRT-PCR) assay to calculate relative transcript abundances of Interleukin-6 (IL-6; Mm00446190_m1) and interferon-γ (IFN-γ; Mm01168134_m1)—both of which were normalized to the expression of our housekeeping gene, beta-2-microglobulin (B2M; Mm0043772_m1). 100 ng of RNA per reaction was reverse-transcribed in a 2720 Thermal Cycler (Life Technologies, Carlsbad, CA, USA) using the Superscript III First-Strand Synthesis System (Life Technologies). Relative transcript abundance was determined via qRT-PCR using TaqMan Gene Expression Assay Primer/Probe Sets and TaqMan MasterMix (Life Technologies in a calibrated StepOnePlus TM Real Time PCR System). Gene expression was analyzed using the 2 −∆∆Ct method by normalizing to β-2m and calculating as fold expression over controls [50].

4.2.6. Immunofluorescent Staining of Mast Cells and Nerves

Flash-frozen labiar tissue samples were embedded in Tissue-Tek Optimal Cutting Temperature compound (Sakura Finetek, Torrance, CA, USA; #4583) and cryosectioned into 12 µm sections on a Leica CM1860 (Wetzlar, Germany). Sections were then rehydrated in phosphate buffered saline (PBS) and fixed in 4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA; #158127; pH 8.5). For mast cell staining, tissues were washed in PBS, permeabilized for 30 min with 0.1% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA; #X100) in PBS, and blocked for one hour in 5% normal donkey serum (Jackson ImmunoResearch Laboratories, West Grove, PA, USA; #017-000-121) in PBS. Slides were then incubated for one hour with Fluorescein Avidin D (Vector Laboratories, Burlingame, CA, USA; # A-2001; 1:1000) in blocking solution. For nerve staining, fixed tissue sections were stained with a primary rabbit polyclonal antibody against calcitonin gene related peptide (CGRP; Abbiotec, San Diego, CA, USA; 1:500) and AlexaFluor 488-conjugated secondary antibody (Thermo Fisher Scientific, Wilmington, DE, USA; 1:1000) as previously described [8,9]. Stained slides were cover-slipped with VECTASHIELD Antifade Mounting Medium with DAPI (Vector Laboratories; Burlingame, CA, USA; H-1200) and left at room temperature for 30 min before freezing at −20 °C.

4.2.7. Confocal Imaging

Sections were imaged using a laser scanning confocal microscope. Composite images of ten optical 1 µm sections projected on the z-axis were analyzed using FluoView FV1000 image analysis software (Olympus Corporation, Center Valley, PA, USA) or ZEN 2.1 Imaging software Version 2.1.57.1000 (Carl Zeiss AG, Oberkochen, Germany). Mast cell density and CGRP + nerve density were determined by fluorescent pixel intensity measurements. Average intensities were calculated from tissue sections pooled from 3–6 mice from each treatment group from 1–2 independent experiments. For mast cells, four representative 5000 µm 2 regions of interest were taken in each of three sections per slide per mouse and 3–6 mice per treatment group. The sum of the values from the four regions of interest were taken and divided by 5000 µm 2 to give a value of average fluorescent intensity/µm 2 for each section quantified. For CGRP + nerves, four representative 5000 µm 2 regions of interest as well as one blank region were measured for three sections per each slide. Readings from the blank region were subtracted from the average of the four representative sections and the resulting value divided by 5000 µm 2 to give an average fluorescent intensity/µm 2 for each section quantified. Each treatment value was then divided by the average control value, and plotted on a fold expansion graph using PRISM 6.0 (GraphPad, San Diego, CA, USA).

4.2.8. Quantification of Local Eosinophil Peroxidase (EPO) and Myeloperoxidase (MPO) Activity

During tissue collection, labiar tissue was weighed, placed in a weight-based volume of 0.5% hexadecyl trimethylammonium bromide (HTAB) buffer (Sigma-Aldrich, St. Louis, MO, USA), and stored at −80 °C. After freezing the tissue for at least 24 h, samples were thawed and four times the original amount of HTAB buffer was added. The samples were homogenized, sonicated, freeze-thawed, re-sonicated, and centrifuged before they were incubated in a substrate solution (16 mmol/L o-phenylenediamine (OPD; Sigma-Aldrich, St. Louis, MO, USA), 50 mM Tris-HCl buffer, and 0.01% H2O2 for 30 min. Absorbance was measured at 490 nm. Eosinophil peroxidase (EPO) levels were normalized to tissue weight and optical density (OD) values per gram of wet tissue were calculated. For MPO measurements, labiar tissue, upon extraction, was placed in a solution of 50 mM K2HPO4 buffer (pH 6.0; Sigma-Aldrich, St. Louis, MO, USA) with 0.05% HTAB and stored at −80 °C. At least 24 h later, the tissue was thawed and homogenized in HTAB buffer. The 5×-diluted homogenate was then sonicated thrice, freeze-thawed thrice, re-sonicated, and centrifuged. After a 20-min incubation in 50 mM phosphate buffer (pH 6.0; Sigma-Aldrich, St. Louis, MO, USA) with 0.025% H2O2 and 0.167 mg/mL o-dianisidine dihydrochloride (Sigma-Aldrich, St. Louis, MO, USA) at room temperature in the dark, absorbance was measured at 450 nm. Myeloperoxidase (MPO) levels were normalized to tissue weight and OD/g of wet tissue calculated.

4.2.9. Lymph Node Processing and Flow Cytometry

Harvested iliac lymph nodes were passed through a 70 μm strainer, washed with staining buffer (2% fetal bovine serum in 1× PBS; Serum Source International, Charlotte, NC, USA) and stained with antibodies for immunophenotyping (1:100 dilution; Table 1 ) in the presence of Fc block (2.4G2; BioXCell) for 30 min on ice, and analyzed on a BD LSR Fortessa X-20 (Becton Dickinson, Franklin Lakes, NJ, USA). Acquired data were analyzed using FlowJo software (Version 10, FlowJo LLC, Ashland, OR, USA). Dead cells were excluded using Ghost Dye-BV510 (Tonbo Biosciences, San Diego, CA, USA).

Table 1

Fluorochrome conjugated monoclonal antibody panel for flow cytometry of hapten treated draining LN samples used to identify distinct cell lineages.

Antigen Color Clone Host Stable Public Identifier Vendor
CD3 BV421 145-2C11 Armenian Hamster AB_2562556 BioLegend
CD4 PECy7 RM4-5 Rat AB_2621829 Tonbo Biosciences
CD8 APC 53-6.7 Rat AB_2621550 Tonbo Biosciences
CD19 BV785 6D5 Rat AB_11218994 BioLegend
Ckit PE ACK2 Rat AB_2621506 Tonbo Biosciences
FcεR1 FITC MAR-1 Hamster AB_10829796 Miltenyi Biotec
Ghost Dye BV510 Tonbo Biosciences
4.2.10. Flank Skin Processing and Flow Cytometry

We used DNFB-challenged flank tissue rather than labiar skin or vaginal canal samples in order to obtain enough cells for analysis. To prepare flank tissue samples, ND4 female Swiss mice were shaved on the back (15 mm × 15 mm) and both flanks (15 mm × 15 mm) 1 day prior to sensitization. All mice were sensitized with a topical application of 25 µL of 0.5% DNFB (Sigma-Aldrich, St. Louis, MO, USA; #D1529-10ML) dissolved in 0.9% saline on the shaved back. Four days after sensitization, mice were challenged on both shaved flanks with 25 µL (50 µL total) of 0.3% DNFB dissolved in 0.9% saline or 0.9% saline alone daily for 10 consecutive days. Leukocytes were isolated from flank skin samples from CO2-euthanized mice as previously described [51] 1 day after the cessation of challenges. Cells were washed, blocked for five minutes with 50 μL of supernatant from a 2.4G2 hybridoma cell line (BioXCell, West Lebanon, NH, USA), stained with fluorochrome-conjugated monoclonal antibodies ( Table 2 ) at 1:100 dilutions for 30 min at 4 °C. and analyzed using an LSR Fortessa X-20 (Becton Dickinson, Franklin Lakes, NJ, USA) flow cytometer. Acquired data were analyzed using FlowJo software (Version 10, FlowJo LLC, Ashland, OR, USA). Dead cells were excluded using Ghost Dye-BV510 (Tonbo Biosciences, San Diego, CA, USA).

Table 2

Fluorochrome conjugated monoclonal antibody panel for flow cytometry of hapten treated flank skin samples used to identify distinct cell lineages.

Antigen Color Clone Host Stable Public Identifier Vendor
CD45.1 APC efluor 780 A20 Mouse AB_1582228 Thermo Fisher
CD45.2 APC efluor 780 104 Mouse AB_1272175 Thermo Fisher
CD3 BUV395 145-2C11 Armenian Hamster BD Biosciences
CD19 BV786 6D5 Rat AB_11218994 BioLegend
CD25 BV650 PC61 Rat AB_11125760 BioLegend
CD8 APC 53-6.7 Rat AB_2621550 Tonbo Biosciences
CD4 PerCP Cy5.5 RM4-5 Rat AB_2621876 Tonbo Biosciences
CD44 efluor 450 IM7 Rat AB_1272250 Thermo Fisher
CD103 FITC 2E7 Armenian Hamster AB_10709438 BioLegend
Ghost Dye BV510 Tonbo Biosciences
4.2.11. IgE Enzyme-Linked Immunosorbent Assay (ELISA)

Serum samples were collected at various timepoints. IgE content in the serum was measured using an IgE ELISA kit (Bethyl Laboratories, Montgomery, TX, USA) after serum was diluted 1:20 in dilution buffer provided with the kit. Absorbances were recorded with a PowerWave XZ microplate spectrophotometer (Biotek Instruments, Winooski, VT, USA) and IgE concentration in each sample was calculated according to the manufacturer’s instructions.

4.2.12. Data Analysis and Visualization

Data were analyzed in Excel 16.16 (Microsoft, Redmond, WA, USA), graphed using PRISM 6.0 (GraphPad, San Diego, CA, USA) and statistically analyzed in JMP 11.2 software (SAS, Cary, NC, USA). One-way ANOVA and post hoc Tukey HSD analyses were used to determine statistical differences between treatment groups and timepoints. Grubbs’ test was used to exclude any outliers. Statistical significance was defined as p < 0.05.

Acknowledgments

These studies were supported by NIH 1R15AI113620-01A1 to DC, the Biology Department at Macalester College and intramural undergraduate summer research stipends from Macalester College. The authors thank Amy Pelz for graphic design, Patty Byrne Pfalz for administrative assistance, Jamie Atkins for animal care, David Matthes for feedback on the manuscript, and past and current members of the Chatterjea lab for their help and support.

Supplementary Materials

Author Contributions

Conceptualization: D.C. and B.B.; Data curation: B.B., E.A.-G. and D.C.; Formal analysis: B.B., R.K., E.A.-G., J.L., E.E., S.J. and M.S.M.; Funding acquisition: D.C.; Investigation, B.B., R.K., E.A.-G., J.L., E.E., S.J. and M.S.M.; Methodology: B.B., T.M. and D.C.; Project administration: D.C.; Resources: D.C. and B.T.F.; Supervision: D.C.; Validation: D.C.; Visualization: B.B., E.A.-G. and D.C.; Writing—original draft: D.C. and B.B.; Writing—review & editing, B.B., R.K., E.A.-G. and D.C.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Pukall C.F., Goldstein A.T., Bergeron S., Foster D., Stein A., Kellogg-Spadt S., Bachmann G. Vulvodynia: Definition, Prevalence, Impact, and Pathophysiological Factors. J. Sex Med. 2016; 13 :291–304. doi: 10.1016/j.jsxm.2015.12.021. [PubMed] [CrossRef] [Google Scholar]

2. Sadownik L.A. Etiology, diagnosis, and clinical management of vulvodynia. Int. J. Womens Health. 2014; 6 :437–449. doi: 10.2147/IJWH.S37660. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

3. Bornstein J., Goldschmid N., Sabo E. Hyperinnervation and mast cell activation may be used as histopathologic diagnostic criteria for vulvar vestibulitis. Gynecol. Obstet. Investig. 2004; 58 :171–178. doi: 10.1159/000079663. [PubMed] [CrossRef] [Google Scholar]

4. Falsetta M.L., Foster D.C., Woeller C.F., Pollock S.J., Bonham A.D., Haidaris C.G., Stodgell C.J., Phipps R.P. Identification of novel mechanisms involved in generating localized vulvodynia pain. Am. J. Obstet. Gynecol. 2015; 213 :38.e1-e12. doi: 10.1016/j.ajog.2015.02.002. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

5. Foster D.C., Piekarz K.H., Murant T.I., LaPoint R., Haidaris C.G., Phipps R.P. Enhanced synthesis of proinflammatory cytokines by vulvar vestibular fibroblasts: Implications for vulvar vestibulitis. Am. J. Obstet. Gynecol. 2007; 196 :346.e1-e8. doi: 10.1016/j.ajog.2006.12.038. [PubMed] [CrossRef] [Google Scholar]

6. Harlow B.L., He W., Nguyen R.H. Allergic reactions and risk of vulvodynia. Ann. Epidemiol. 2009; 19 :771–777. doi: 10.1016/j.annepidem.2009.06.006. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

7. Reed B.D., McKee K.S., Plegue M.A., Park S.K., Haefner H.K., Harlow S.D. Environmental Exposure History and Vulvodynia Risk: A Population-Based Study. J. Womens Health. 2019; 28 :69–76. doi: 10.1089/jwh.2018.7188. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Landry J., Martinov T., Mengistu H., Dhanwada J., Benck C.J., Kline J., Boo B., Swanson L., Tonc E., Daughters R., et al. Repeated hapten exposure induces persistent tactile sensitivity in mice modeling localized provoked vulvodynia. PLoS ONE. 2017; 12 :e0169672. doi: 10.1371/journal.pone.0169672. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

9. Martinov T., Glenn-Finer R., Burley S., Tonc E., Balsells E., Ashbaugh A., Swanson L., Daughters R.S., Chatterjea D. Contact hypersensitivity to oxazolone provokes vulvar mechanical hyperalgesia in mice. PLoS ONE. 2013; 8 :e78673. doi: 10.1371/journal.pone.0078673. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

10. Dudeck A., Dudeck J., Scholten J., Petzold A., Surianarayanan S., Köhler A., Peschke K., Vöhringer D., Waskow C., Krieg T., et al. Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. Immunity. 2011; 24 :973–984. doi: 10.1016/j.immuni.2011.03.028. [PubMed] [CrossRef] [Google Scholar]

11. Kraneveld A.D., van der Kleij H.P., Kool M., van Houwelingen A.H., Weitenberg A.C., Redegeld F.A., Nijkamp F.P. Key role for mast cells in nonatopic asthma. J. Immunol. 2002; 169 :2044–2053. doi: 10.4049/jimmunol.169.4.2044. [PubMed] [CrossRef] [Google Scholar]

12. Dudeck J., Medyukhina A., Fröbel J., Svensson C.M., Kotrba J., Gerlach M., Gradtke A.C., Schröder B., Speier S., Figge M.T., et al. Mast cells acquire MHCII from dendritic cells during skin inflammation. J. Exp. Med. 2017; 4 :3791–3811. doi: 10.1084/jem.20160783. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Honda T., Egawa G., Grabbe S., Kabahima K. Update of immune events in the murine contact hypersensitivity model: Towards the understanding of allergic contact dermatitis. J. Investig. Dermatol. 2013; 133 :303–315. doi: 10.1038/jid.2012.284. [PubMed] [CrossRef] [Google Scholar]

14. Schneider C., Döcke W.D., Zollner T.M., Röse L. Chronic mouse model of TMA-induced contact hypersensitivity. J. Investig. Dermatol. 2009; 129 :899–907. doi: 10.1038/jid.2008.307. [PubMed] [CrossRef] [Google Scholar]

15. Yu M., Eckart M.R., Morgan A.A., Mukai K., Butte A.J., Tsai M., Galli S.J. Identification of an IFN-γ/mast cell axis in a mouse model of chronic asthma. J. Clin. Investig. 2011; 121 :3133–3143. doi: 10.1172/JCI43598. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

See also  Cbd oil for etd

16. Gaffal E., Cron M., Glodde N., Tüting T. Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors. Allergy. 2013; 68 :994–1000. doi: 10.1111/all.12183. [PubMed] [CrossRef] [Google Scholar]

17. Nam G., Jeong S.K., Park B.M., Lee S.H., Kim H.J., Hong S.P., Kim B., Kim B.W. Selective Cannabinoid Receptor-1 Agonists Regulate Mast Cell Activation in an Oxazolone-Induced Atopic Dermatitis Model. Ann. Dermatol. 2016; 28 :22–29. doi: 10.5021/ad.2016.28.1.22. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

18. Chatterjea D., Martinov T. Mast cells: Versatile gatekeepers of pain. Mol. Immunol. 2015; 63 :38–44. doi: 10.1016/j.molimm.2014.03.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

19. Galli S.J., Kalesnikoff J., Grimbaldeston M.A., Piliponsky A.M., Williams C.M., Tsai M. Mast cells as “tunable” effector and immunoregulatory cells: Recent advances. Annu. Rev. Immunol. 2005; 23 :749–786. doi: 10.1146/annurev.immunol.21.120601.141025. [PubMed] [CrossRef] [Google Scholar]

20. Chatterjea D., Wetzel A., Mack M., Engblom C., Allen J., Mora-Solano C., Paredes L., Balsells E., Martinov T. Mast cell degranulation mediates compound 48/80-induced hyperalgesia in mice. Biochem. Biophys. Res. Commun. 2012; 425 :237–243. doi: 10.1016/j.bbrc.2012.07.074. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

21. Mack M., Tonc E., Ashbaugh A., Wetzel A., Sykes A., Engblom C., Shabani E., Mora-Solano C., Trier A., Swanson L., et al. Clonal differences in IgE antibodies affect cutaneous anaphylaxis-associated thermal sensitivity in mice. Immunol. Lett. 2014; 162 :149–158. doi: 10.1016/j.imlet.2014.08.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

22. Levy D. Migraine pain, meningeal inflammation, and mast cells. Curr. Pain Headache Rep. 2009; 13 :237–240. doi: 10.1007/s11916-009-0040-y. [PubMed] [CrossRef] [Google Scholar]

23. Vincent L., Vang D., Nguyen J., Gupta M., Luk K., Ericson M.E., Simone D.A., Gupta K. Mast cell activation contributes to sickle cell pathobiology and pain in mice. Blood. 2013; 122 :1853–1862. doi: 10.1182/blood-2013-04-498105. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

24. Ng Q.X., Soh A.Y.S., Loke W., Lim D.Y., Yeo W.S. The role of inflammation in irritable bowel syndrome (IBS) J. Inflamm. Res. 2018; 11 :345–349. doi: 10.2147/JIR.S174982. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

25. Kaur G., Singh N., Jaggi A.S. Mast cells in neuropathic pain: An increasing spectrum of their involvement in pathophysiology. Rev. Neurosci. 2017; 28 :759–766. doi: 10.1515/revneuro-2017-0007. [PubMed] [CrossRef] [Google Scholar]

26. Hendriksen E., van Bergeijk D., Oosting R.S., Redegeld F.A. Mast cells in neuroinflammation and brain disorders. Neurosci. Biobehav. Rev. 2017; 79 :119–133. doi: 10.1016/j.neubiorev.2017.05.001. [PubMed] [CrossRef] [Google Scholar]

27. Bornstein J., Cohen Y., Zarfati D., Sela S., Ophir E. Involvement of heparanase in the pathogenesis of localized vulvodynia. Int. J. Gynecol. Pathol. 2008; 27 :136–141. doi: 10.1097/pgp.0b013e318140021b. [PubMed] [CrossRef] [Google Scholar]

28. Papoutsis D., Haefner H.K., Crum C.P., Opipari A.W., Jr., Reed B.D. Vestibular mast cell density in vulvodynia: A case-controlled study. J. Low. Genit. Tract. Dis. 2016; 20 :275–279. doi: 10.1097/LGT.0000000000000221. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

29. Vieira-Baptista P., Lima-Silva J., Pérez-López F.R., Preti M., Bornstein J. Vulvodynia: A disease commonly hidden in plain sight. Case Rep. Womens Health. 2018; 20 :e00079. doi: 10.1016/j.crwh.2018.e00079. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

30. Harlow B.L., Caron R.E., Parker S.E., Chatterjea D., Fox M.P., Nguyen R.H.N. Recurrent Yeast Infections and Vulvodynia: Can We Believe Associations Based on Self-Reported Data? J. Womens Health (Larchmt) 2017; 26 :1069–1076. doi: 10.1089/jwh.2016.5777. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

31. Nguyen R.H., Swanson D., Harlow B.L. Urogenital infections in relation to the occurrence of vulvodynia. J. Reprod. Med. 2009; 54 :385–392. [PubMed] [Google Scholar]

32. Khandker M., Brady S.S., Vitonis A.F., Maclehose R.F., Stewart E.G., Harlow B.L. The influence of depression and anxiety on risk of adult onset vulvodynia. J. Womens Health (Larchmt) 2011; 20 :1445–1451. doi: 10.1089/jwh.2010.2661. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

33. Jones T.G., Finkelman F.D., Austen K.F., Gurish M.F. T regulatory cells control antigen-induced recruitment of mast cell progenitors to the lungs of C57BL/6 mice. J. Immunol. 2010; 185 :1804–1811. doi: 10.4049/jimmunol.1001146. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

34. Yu M., Tsai M., Tam S.Y., Jones C., Zehnder J., Galli S.J. Mast cells can promote the development of multiple features of chronic asthma in mice. J. Clin. Investig. 2006; 116 :1633–1641. doi: 10.1172/JCI25702. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

35. Schenkel J.M., Fraser K.A., Vezys V., Masopust D. Sensing and alarm function of resident memory CD8⁺ T cells. Nat. Immunol. 2013; 14 :509–513. doi: 10.1038/ni.2568. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

36. Asai K., Kitaura J., Kawakami Y., Yamagata N., Tsai M., Carbone D.P., Liu F.T., Galli S.J., Kawakami T. Regulation of mast cell survival by IgE. Immunity. 2001; 14 :791–800. doi: 10.1016/S1074-7613(01)00157-1. [PubMed] [CrossRef] [Google Scholar]

37. Bax H.J., Keeble A.H., Gould H.J. Cytokinergic IgE action in mast cell activation. Front. Immunol. 2012; 3 :229. doi: 10.3389/fimmu.2012.00229. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

38. Wang H.W., Tedla N., Lloyd A.R., Wakefield D., McNeil P.H. Mast cell activation and migration to lymph nodes during induction of an immune response in mice. J. Clin. Investig. 1998; 102 :1617–1626. doi: 10.1172/JCI3704. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

39. Forsythe P., Bienenstock J. The mast cell-nerve functional unit: A key component of physiologic and pathophysiologic responses. Chem. Immunol. Allergy. 2012; 98 :196–221. [PubMed] [Google Scholar]

40. Skaper S.D. Nerve Growth factor: A neuroimmune crosstalk mediator for all seasons. Immunology. 2017; 151 :1–15. doi: 10.1111/imm.12717. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

41. Hagiyama M., Inoue T., Furuno T., Iino T., Itami S., Nakanishi M., Asada H., Hosokawa Y., Ito A. Increased expression of cell adhesion molecule 1 by mast cells as a cause of enhanced nerve-mast cell interaction in a hapten-induced mouse model of atopic dermatitis. Br. J. Dermatol. 2013; 168 :771–778. doi: 10.1111/bjd.12108. [PubMed] [CrossRef] [Google Scholar]

42. Nyirjesy P., Sobel J., Weitz M., Leaman D., Small M., Gelone S. Cromolyn cream for recalcitrant idiopathic vulvar vestibulitis: Results of a placebo controlled study. Sex Transm. Infect. 2001; 77 :53–57. doi: 10.1136/sti.77.1.53. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

43. Starowicz K., Finn D.P. Cannabinoids and Pain: Sites and Mechanisms of Action. Adv. Pharmacol. 2017; 80 :437–475. [PubMed] [Google Scholar]

44. Vincent L., Vang D., Nguyen J., Benson B., Lei J., Gupta K. Cannabinoid receptor-specific mechanisms to alleviate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation. Haematologica. 2016; 101 :566–577. doi: 10.3324/haematol.2015.136523. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

45. Singh U., Singh N., Singh B., Price R., Nagarkatti M., Nagarkatti P. Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(−/−) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol. Appl. Pharmacaol. 2012; 258 :256–267. doi: 10.1016/j.taap.2011.11.005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

46. Khan S.P., Pickens T.A., Berlau D.J. Perspectives on cannabis as a substitute for opioid analgesics. Pain Manag. 2019; 9 :191–203. doi: 10.2217/pmt-2018-0051. [PubMed] [CrossRef] [Google Scholar]

47. Aviram J., Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: A systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017; 20 :E755–E796. [PubMed] [Google Scholar]

48. Martinov T., Mack M., Sykes A., Chatterjea D. Measuring changes in tactile sensitivity in the hind paw of mice using an electronic von Frey apparatus. J. Vis. Exp. 2013; 19 :e51212. doi: 10.3791/51212. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

49. Farmer M.A., Taylor A.M., Bailey A.L., Tuttle A.H., MacIntyre L.C., Milagrosa Z.E., Crissman H.P., Bennett G.J., Ribeiro-da-Silva A., Binik Y.M., et al. Repeated vulvovaginal fungal infections cause persistent pain in a mouse model of vulvodynia. Sci. Transl. Med. 2011; 3 :101ra91. doi: 10.1126/scitranslmed.3002613. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

50. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25 :402–408. doi: 10.1006/meth.2001.1262. [PubMed] [CrossRef] [Google Scholar]

51. Benck C.J., Martinov T., Fife B.T., Chatterjea D. Isolation of Infiltrating Leukocytes from Mouse Skin Using Enzymatic Digest and Gradient Separation. J. Vis. Exp. 2016; 107 :e53638. doi: 10.3791/53638. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Articles from International Journal of Molecular Sciences are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

How To Use Medical Marijuana for Vulvodynia

Vulvodynia is a mysterious medical condition characterized by chronic pain in the vulva, labia, and the skin surrounding the opening of the vagina. The condition can cause persistent, burning, stinging, throbbing, and soreness. It can be triggered by touch or the pain can be continuous. It can adversely affect the patient’s sex life and be emotionally distressing.

Vulvodynia can be an extremely painful and even debilitating medical condition. Can medical marijuana help provide relief for women suffering from this extremely unpleasant and distressing condition? As more and more U.S. states add chronic pain as a qualifying condition for a medical marijuana card , increasing numbers of women are shopping at dispensaries nationwide .

Scientific and anecdotal evidence suggests that medical marijuana and cannabis-infused medications can help to reduce the symptoms of vulvodynia in some patients. Cannabis also helps some patients suffering from other chronic and painful gynecological conditions such as endometriosis.

Traditional treatments for vulvodynia can have limited effectiveness and come with the potential for long-term side effects. Many vulvodynia patients are finding that medical marijuana offers a natural alternative that is safe and effective when used properly.

How does medical marijuana help treat vulvodynia?

Marijuana produces a class of compounds called phytocannabinoids that have been shown to help reduce inflammation and modulate pain response. Cannabinoids have also been shown to help reduce stress and anxiety , relax muscles , relieve pain, improve sleep , and reduce depression in some patients suffering from vulvodynia.

Cannabinoids found in marijuana act upon the human body in much the same way as endocannabinoids produced by the human body . Endocannabinoids are produced in the brain in response to imbalances within the body. They enter the bloodstream and circulate throughout the body relaying instruction to individual cells. This signaling system is referred to as the human endocannabinoid system or ECS.

Two major cannabinoids — THC and CBD — and several other minor cannabinoids including CBG and CBN are produced in the resinous flowers of the female cannabis plant.

While THC can produce intoxication when used in sufficient quantities, most other cannabinoids do not. However, a cannabinoid not usually found in cannabis called delta-8 THC can be created from CBD. D8 THC can produce slightly intoxicating properties in some patients while offering some of the medicinal benefits specific to CBD.

The various cannabinoids produced in medical marijuana affect each patient differently. The trick is for the patient to find the right balance of cannabinoids to produce maximum relief. This often takes some educated experimentation.

Is there any scientific evidence that medical marijuana can help treat vulvodynia?

Vulvodynia is not a common medical condition and as such has not been the subject of significant cannabis-related research. However, preclinical evidence suggests that cannabinoids may reduce labial sensitivity by reducing inflammatory mast cells (a type of white blood cell found in connective tissue). Medical conditions of the vulva are often accompanied by increases in these mast cells.

Data from an online survey was studies to help determine the effectiveness of cannabis in treating vulvodynia. Participants in the survey reported that the more severe their symptoms, the more effective medicinal marijuana was at reducing pain.

In another study, THC and saline were administered into the vaginal canal of mice who were sensitized to vulvar pain. Researchers reported that the mice that received the THC experienced approximately 60 percent reduction in vaginal pain.

Links to these studies and others associated with the use of cannabis in treating chronic pain can be found at the end of the article.

How to treat vulvodynia with medical marijuana

The vaginal canal has a mucosal lining through which medications can be quickly absorbed into the body. For this reason, cannabis suppositories are a common method for treating conditions of the vagina. Cannabinoid-infused topical creams and ointments applied at the site of pain might also help some patients.

When using suppositories or topicals, it’s important to use only high-qualify medications that are produced specifically for vaginal use.

For patients suffering from sudden onset of pain, other systemic delivery methods might help provide fast relief. Smoking , vaping , dabbing , and inhalers offer almost instant effects as the cannabinoids are absorbed directly into the bloodstream through the lungs. Patients with lung or circulatory conditions might be best served with an inhaler that contains only pure cannabinoids and no smoke or vapor.

Cannabinoid-infused products such as edibles , capsules , powders, tinctures , oils , patches , and inhalers can be used orally and sublingually (under the tongue). These products can be produced with very specific cannabinoid ratios and formulations. However, the onset time of oral cannabis products is slower and less enters the bloodstream, especially when taken with a meal.

Products containing THC may only be purchased legally at medical marijuana dispensaries nationwide. However, cannabinoids produced from hemp such as CBD, CBG, CBN, and D8THC are all available over-the-counter. Anyone can buy CBD online or at local shops without a medical marijuana card.

TMJ patients should not be self-medicating and are strongly advised to consult with a knowledgeable medical marijuana doctor .